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Abstract
Background—Cervical cancer kills more women in low-income nations than any other 
malignancy. A variety of research and demonstration efforts have proven the efficacy and 
effectiveness of low-cost cervical cancer prevention methods but none in routine program 
implementation settings of the developing world, particularly in HIV-infected women.
Methods—In our public sector cervical cancer prevention program in Zambia, nurses conduct 
screening using visual inspection with acetic acid aided by digital cervicography. Women with 
visible lesions are offered same-visit cryotherapy or referred for histologic evaluation and clinical 
management. We analyzed clinical outcomes and modeled program effectiveness among HIV-
infected women by estimating the total number of cervical cancer deaths prevented through 
screening and treatment.
Results—Between 2006 and 2008, 6572 HIV-infected women were screened, 53.6% (3523) had 
visible lesions, 58.5% (2062) were eligible for cryotherapy and 41.5% (1461) were referred for 
histologic evaluation. A total of 75% (1095 out of 1462) of patients who were referred for 
evaluation complied. Pathology results from 65% (715 out of 1095) of women revealed benign 
abnormalities in 21% (151), cervical intraepithelial neoplasia (CIN) I in 30% (214), CIN 2/3 in 
33% (235) and invasive cervical cancer in 16.1% (115, of which 69% were early stage). Using a 
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conditional probability model, we estimated that our program prevented 142 cervical cancer 
deaths (high/low range: 238–96) among the 6572 HIV-infected women screened, or one cervical 
cancer death prevented per 46 (corresponding range: 28–68) HIV-infected women screened.
Conclusion—Our prevention efforts using setting-appropriate human resources and technology 
have reduced morbidity and mortality from cervical cancer among HIV-infected women in 
Zambia. Financial support for implementing cervical cancer prevention programs integrated 
within HIV/AIDS care programs is warranted. Our prevention model can serve as the 
implementation platform for future low-cost HPV-based screening methods, and our results may 
provide the basis for comparison of programmatic effectiveness of future prevention efforts.
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Invasive cervical cancer (ICC) remains the leading cause of cancer-related mortality and 
morbidity in low-income countries of the developing world [1,2]. Over the past decade, a 
variety of efforts (including randomized clinical trials) have demonstrated the utility of 
noncytological prevention methods such as visual inspection with acetic acid (VIA) and 
human papilloma-virus (HPV)–DNA testing [3,4]. While such efforts have shown the 
safety, acceptability, feasibility and clinical effectiveness of such ‘screen and treat’ (linking 
screening test results to immediate cryotherapy) prevention services for reducing cervical 
cancer incidence and mortality in the developing world, measuring effectiveness in routine 
program implementation settings has remained a challenge [3-6].
HIV-infected women are at high risk for developing cervical intraepithelial neoplasia (CIN) 
and ICC when they are persistently coinfected with oncogenic HPV genotypes, 
immunosuppressed due to HIV and without access to effective cervical cancer screening 
services [7-9]. Such circumstances characterize large numbers of HIV-infected women 
residing in low-income nations, at a time when their life spans are being prolonged due to 
expanded access to effective antiretroviral therapy and medical care [10,11]. Our previous 
efforts demon strated an extraordinarily high burden of HPV and cervical disease among 
HIV-infected women in Zambia [7,12]. This prompted us to launch a cervical cancer 
prevention program targeting HIV-infected women, with the ultimate goal of expanding to 
all Zambian women and decreasing cervical cancer-associated morbidity and mortality. Our 
effort was supported by a partnership between Zambian and US academic (University 
Teaching Hospital [UTH] in Lusaka; University of Alabama in Birmingham [UAB]), 
research (Centre for Infectious Disease Research in Zambia [CIDRZ]) and government 
(Zambian Ministry of Health) partner institutions. Prevention efforts have been scaled up 
rapidly over 3 years with substantial assistance from the US President’s Emergency Plan for 
AIDS Relief (PEPFAR) and have cumulatively provided screening services to over 52,000 
women as of 1st October 2010 [13-15]. In this Research Article, we systemati-
systematically analyze these implementation efforts by measurement and modeling of the 
real-world program effectiveness through measurement of outcomes of program uptake, 
screening test efficacy and treatment effectiveness, and then extrapolating its impact on 
reductions in mortality.
Parham et al. Page 2























The program implementation details have been published previously [13-15]. Brie y, 
cervical can-y, cervical cancer prevention services are located within government-operated 
public health clinics that provide much of the primary care for a large majority of Zambians. 
PEPFAR-funded, UAB–CIDRZ-supported HIV care and treatment services in Zambia are 
tightly integrated into 53 of these government-operated facilities [10]. Since the cervical 
cancer program’s inception in January 2006, 18 Zambian nurses have been trained in 
conducting cervical cancer screening examinations by VIA. We added digital imaging of the 
cervix through a portable commercial brand digital camera (digital cervicography) as a 
routine adjunct to VIA to assist with patient and provider education and quality control [14]. 
Nurses operate independently in rooms co-located within 15 public health clinics (11 urban 
and four rural) operated by the Zambian Ministry of Health. Women who test VIA positive 
and have eligible lesions are offered cryotherapy immediately following screening [13,15]. 
When necessary, nurses consult local gynecologists by distance consultation using electronic 
transfer of digital photographs of the screened cervix to help make the appropriate 
cryotherapy or referral decisions [14]. Those with lesions requiring histological evaluation 
are referred to a Gynecologic Cancer Prevention Unit at UTH [15]. All tissue specimens 
were interpreted in Zambia by a board-certified Zambian senior pathologist (VM) in the 
Department of Pathology at UTH. Patients diagnosed with ICC are treated at UTH (surgery) 
and the Cancer Diseases Hospital (radiation/chemotherapy), depending on the stage of 
disease and medical condition of the patient. Basic sociodemographic and clinical data are 
transferred from paper-based clinic records to a centralized electronic medical records 
database. Follow-up visits for those undergoing local ablative (cryotherapy) or excisional 
therapy using the loop electrosurgical excision procedure (LEEP), in a ’see and LEEP’ 
format (i.e., electrosurgical excision guided by digital camera photographic images and 
without preceding punch biopsies), are encouraged at 6 weeks (assess complications, discuss 
pathology report) and 6 and 12 months (for rescreening by digital cervicography-aided VIA 
to detect persistent and recurrent lesions). Annual screening is recommended for all, 
including those who initially screened negative, for continued surveillance of cervical 
disease status. Following all treatments, women are specifically asked to avoid sexual 
intercourse for 6 weeks and are provided condoms to reduce the risk of infection (to a 
woman if she is HIV-uninfected or to her and her partner if the woman is HIV-infected) in 
case intercourse cannot be avoided.
In this analysis, we measured the clinical and programmatic outcomes of women (all women 
and HIV-infected women) enrolled in the cervical cancer prevention program. Their 
demographic characteristics are summarized using means and standard deviations or 
medians and interquartile ranges (for continuous variables) and frequency counts and 
percentages (for categorical variables). We used this information and other published 
literature to develop a conditional probability model to estimate program effectiveness, as 
measured by the total number of cervical cancer deaths prevented among the screened 
population of HIV-infected women as a result of these early detection and treatment 
interventions. We performed sensitivity (uncertainty) analyses, estimating potential high and 
low effects, using varying assumptions from the published literature of three major attributes 
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that determine screening program effectiveness: first, performance of the screening test, as 
measured by the predictive value of a positive screening test (digital cervicography-aided 
VIA) [16-18]; second, progression rate [8,19-23] of the disease as informed by natural 
history studies; and third, cure rates [24-26] for various treatment modalities including 
cryotherapy, local excision, surgery and chemo/radiation therapy, for all grades of 
preinvasive neoplasia (CIN 1–3) and stages of cancer (1A–IV).
For neoplasia grades and cancer stages; the number of observed cases was first multiplied by 
the positive predictive value estimate of the screening test to get the estimate of the ‘true’ 
disease cases that were prevented. This was then multiplied by the progression rate to arrive 
at the estimated number of cancer cases that would have occurred had the disease gone 
untreated. The estimated number of cancer cases was then multiplied by the cure rates to 
determine the number of cancer deaths prevented, which was further used to estimate the 
number of women needed to be screened to prevent one death due to cervical cancer in the 
population of HIV-infected women screened. Sensitivity analyses were performed to 
examine the impact of various combinations (n = 27) of high, low and average estimates of 
predictive values of a positive screening test, disease progression rates and cure rates by 
various treatment modalities on our estimate. The global literature used for assumptions in 
our sensitivity range estimates were from limited studies among HIV-infected women or 
from estimates from the general population when no such data are available from studies in 
HIV-infected women (e.g., progression/cure rates for various stages of ICC). Analyses were 
performed using SAS™ v9.13 (SAS Institute, Cary, NC, USA) and Microsoft Excel™ 
(Microsoft Corporation, Redmond, WA, USA).
Results
Clinical outcomes & uptake indicators
From January 2006 through December 2008, we screened 21,010 women for cervical 
cancer, of whom 6572 (31.3%) were HIV infected, 7374 (35.1%) were HIV seronegative 
while HIV serostatus was unknown in 7064 (33.6%) women (Figure 1). Selected relevant 
socio demographic characteristics of the HIV-infected population were mean age: 34.2 years 
(SD ± 8.0); mean age at first sex: 17.6 years (SD ± 2.6); 49% with primary school education 
or below; 68% with income less than 500,000 kwacha/month (~US$125/month or US$ 4/
day); and 53% married and cohabitating with their husbands. Median CD4+ T-cell count 
was 189/μl (interquartile range: 100–309) (Table 1).
More than half (54% [3523/6572]) of the HIV-infected women who underwent screening 
had evidence of a visually apparent lesion suggestive of precancer (‘VIA positive’), of 
whom about three-fifths (59% [2061/3523]) had visual lesions eligible for cryotherapy. Of 
these women eligible for ablative treatment by cryotherapy, 78% (1603/2061) actually 
underwent treatment, two-thirds (1079/1603) on the same day as screening and the rest 
(524/1603) delayed treatment, for which the median time of delay was 11 days (interquartile 
range: 4–56.5 days). The remaining 22% (458/2061) who were eligible for cryotherapy 
never returned for treatment. 75% (1095/1462) of HIV-infected women referred for 
histologic evaluation were compliant with recommendations to attend the Gynecologic 
Cancer Prevention Clinic at the UTH, while 25% (367/1462) were ‘no shows’. Pathology 
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reports were available for 65% (715/1095) of patients that underwent histologic evaluation, 
while the rest (35% [380/1095]) were not available (lost before data entry, lost during record 
keeping or had a loss of specimen during processing). The pathology results included benign 
abnormalities in 151 out of 715 (21%), CIN 1 in 214 out of 715 (30%), CIN 2/3 in 235 out 
of 715 (33%) and ICC in 115 out of 715 (16.1%). Early stage (1A-1B) cancers made up over 
two third (69% [79/115]) of ICCs (Figure 2).
Indicators of program uptake, follow-up and treatment outcomes revealed that over a third 
(35%) of HIV-infected women underwent either ablative (cryotherapy) or excisional (LEEP) 
treatment (Figure 3). However, less than 20% of women ever returned for their 
recommended follow-up visit (6 months for those undergoing cryotherapy or LEEP) and 1 
year (for VIA-negative women) (Figure 4). Visual lesions were ‘positive’ (suggestive of 
recurrent or persistent lesions) in about a third (34% [89/260]) of the HIV-infected women 
treated with cryotherapy who returned for follow-up at 6 months. Among these women, 
available histological evaluation (by LEEP excision) revealed CIN 2+ lesions in 34% 
(18/53). Among HIV-infected women undergoing LEEP who returned for a 6-month follow-
up, visual lesions were ‘positive’ in over two thirds (68% [64/94]). Among these, CIN 2+ on 
histology was present in 40% (19/47) women who underwent repeat excision (Figure 5).
Modeling program effectiveness
Using the average estimates from our data of the three aforementioned attributes that would 
impact program effectiveness, we estimated that 142 cancer deaths were prevented by 
screening 6572 HIV-infected women, or one cancer death averted for every 46 HIV-infected 
woman screened (Table 2 & Figure 6). Using the 27 permutation combinations of low, 
average and high estimates of the positive predictive value, progression rates and cure rates 
(as estimated from our global literature review), we estimate that our program prevented 
between 238 (high estimate for high predictive value, high progression rate and high cure 
rate) and 96 (low estimate for low predictive value, low progression rate and low cure rate) 
cervical cancer deaths in 6572 HIV-infected women, a range of one cervical cancer death 
prevented for every 28–68 HIV-infected women screened, respectively (Figure 6).
Discussion
Zambia has the second highest incidence rates of ICC in the world (52.8 per 100,000 
women) [27] and its HIV prevalence is also among the world’s highest (over 20% in 
reproductive age group adults in 2008) [28,29]. The high background cervical disease 
prevalence among HIV-infected women (as demonstrated by the high screen positive rate of 
53%, and histologically confirmed prevalence of 63% CIN [all grades], 32% CIN 2/3, and 
16% ICC among those referred; much higher than other studies in similar populations 
[30-32]) is juxtaposed with the severe lack of availability and access to screening. In this 
low-income African nation in which less than 5% of the population had ever been screened 
for cervical cancer [2], knowledge of cervical cancer is fraught with myths and 
misunderstandings [33]. Nevertheless, more than 21,000 women voluntarily accessed our 
nurse-led ‘screen and treat’ cervical cancer prevention services during the first 3 years of 
program operations; more than 6,500 of these women were HIV-infected.
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The Zambian Cervical Cancer Prevention Program is the first large-scale public sector 
cervical cancer prevention intervention effort within PEPFAR-supported programs. 
Although initiated as an intervention targeting HIV infected women, cervical cancer 
prevention is now part of routine health service delivery for Zambian women, regardless of 
HIV serostatus as a result of our program. The results of the effectiveness model points to 
the major life-saving potential of an ‘once-in-a-lifetime’ screening and treatment 
intervention for cervical cancer that was integrated with an ongoing HIV/AIDS care and 
treatment program in one of the most resource-limited settings in sub-Saharan Africa. It also 
points to a very high ‘intervention-to-impact’ ratio, especially on the background of a very 
high prevalence of cervical neoplastic disease and HIV prevalence in this population. The 
rate of being able to prevent one cancer death for every 46 HIV-infected women screened is 
therefore re ective of the substantial impact that a screening program can deliver in 
previously unscreened populations with high prevalence rates.
Our conditional probability model, while comprehensive, must be viewed through the prism 
of the substantial limitations that are inherent in parameter inputs and assumptions, 
especially when very limited rigorously collected primary data exists from similar settings 
and populations [34]. Obvious limitations are the validity of the assumptions used for 
predictive values, progression rates and cure rates. We relied on the few studies reporting 
performance of digital cervicography-aided VIA [16-18], although none were reporting 
specifically among HIV-infected women. Natural history studies of cervical neoplasia in 
HIV-infected women are few in number [19,21,35-37], and those that do exist differ in 
terms of median age and length of patient follow-up, histologic confirmation, degree of 
HIV-related immunosuppression and ARV status, all of which can impact results. Likewise, 
to the best of our knowledge there is little in the literature describing 5-year survival rates 
following radiotherapy or surgery for cervical cancer in HIV-infected patients [25,26]. 
Indeed, progression rates between various stages of cancer can be different, and this 
difference is modulated by the timing of their detection and ultimate treatment [38]. 
However, the lack of any data on this ‘down-staging’ effect made it impractical to include it 
in the model. We thus gauged the impact of the wide variation of estimates of predictive 
values, progression and cure rates by computing values of 27 permutation and combinations 
of low, average and high estimates of these three attributes for our model. In absence of hard 
data to inform these assumptions, this ana lysis only provides us the basis for comparison for 
future program effectiveness studies that may incorporate new data on natural history and 
treatment of HPV/cervical disease in HIV-infected women, as well as refined measures of 
programmatic inputs and outcomes (cost–effectiveness ana lysis of this effort is currently 
underway). Finally, we did not account for the impact of follow-up rates on treatment 
effectiveness in this model. Participation and follow-up rates require a whole series of 
assumptions, most of which are dependent on local factors such as the sociocultural context, 
women’s economic capacity and preferences, and success of outreach efforts. In any case, 
those are not linked to parameters of natural history or clinical treatment that were derived 
from our program outcomes or extrapolated from similar studies from other HIV-infected 
populations to develop this model. Future research efforts to refine our estimates should 
undertake variability in follow-up rates and other extraneous factors that might affect 
program effectiveness.
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Outcomes from intensively followed cohorts of HIV-infected women from resource-rich 
settings [36,39-41] clearly demonstrate that death from ICC can be prevented if the disease 
is detected early, appropriate treatment is accessible, timely pathologic ana lysis is available, 
and mechanisms for effective follow-up are in place. While the outcomes of our program 
clearly demonstrate that we can address some if not all of these pre-requisites through 
integrated programming, substantial challenges still remain. Our treatment effectiveness 
indicators are still low, and are re ective of the substantial HPV disease burden and cervical 
disease milieu [7,12], as well as the limitations in treatment methods and provider 
efficiency. We face serious challenges associated with adherence to follow-up 
recommendations and an under-capacitated laboratory infrastructure. These circumstances 
are endemic to the environment in which we operate and represent major limitations to the 
success of our prevention efforts. However, with sustained support through a spectrum of 
funding agencies we are addressing most of these issues head-on with an overarching goal 
for providing the best quality of care for all Zambian women accessing our program.
Each year over half a million women will continue to be newly diagnosed with ICC 
globally, and in the same period over a quarter of a million will die [1]. The vast majority of 
these women reside in low-income nations such as Zambia, where less than 5% of women 
are ever screened in their lifetime for cervical cancer [2]. HPV-based primary (i.e., vaccine) 
and secondary (i.e., HPV-based screening) approaches have the potential to significantly 
reduce the global cervical cancer burden over the following decades. However, successful 
implementation of future molecular HPV-based prevention methods can benefit by the 
availability of suitable clinical platforms such as the one established through our program. 
Innovative approaches to disease prevention must avoid placing additional burdens on health 
systems that are already overburdened. One such strategy is to use the availability, 
momentum and capacity building efforts resulting from vertical HIV/AIDS care and 
treatment programs to implement other disease-specific initiatives such as cervical cancer 
prevention [42]. Our program provides the much-needed evidence about the usefulness of 
such integrative approaches. By using a setting-appropriate protocol for cervical cancer 
prevention, for example, nurse-led visual screening and same-visit cryotherapy for eligible 
women, and linkage to a tertiary care centre for evaluation, our program has not just saved 
lives but has also established a new paradigm for routine prevention interventions in 
resource-constrained environments.
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Figure 1. Cumulative patient enrollment from January 2006 to December 2008, Zambian 
Cervical Cancer Prevention Program (n = 21,010)
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Figure 2. Patient flow chart for clinical screening and care in the Zambian Cervical Cancer 
Prevention Program
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Figure 3. Indicators of participation in screening program (all women and HIV-infected women)
LEEP: Loop electrosurgical excision procedure; VIA: Visual inspection with dilute acetic 
acid.
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Figure 4. Rates of follow-up among HIV-infected women at the recommended 6 month or 1 year 
visits effectiveness
LEEP: Loop electrosurgical excision procedure; VIA: Visual inspection with dilute acetic 
acid.
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Figure 5. Indicators of treatment effectiveness among HIV-infected women who return for 
follow-up at 6 months post-cryotherapy or post-LEEP procedures
LEEP: Loop electrosurgical excision procedure.
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Figure 6. Tornado graph showing the uncertainty ana lysis for the conditional probability model 
to measure program effectiveness of the Zambian Cervical Cancer Prevention Program
The Tornado graph shows trend in the estimates of: total number of cervical cancer deaths 
prevented (blue bars); and total number of women needed to be screened to prevent one 
cervical cancer death (red bars). The graph shows 27 permutation/combinations of the three 
scenarios: ‘base’ case, ‘high’ estimates and ‘low’ estimates of the three major attributes used 
in the conditional probability model; (i) measure of test performance (as measured by the 
PPV), (ii) disease PR and (iii) CR for various treatment modalities. The estimates of the total 
cancer deaths prevented estimated under each permutation/combination are arranged in a 
declining order on the left axis. The corresponding number of women needed to prevent one 
cancer death under that scenario, plotted along the same axis, is shown in ascending order. 
The outcomes of the model in the base case scenario are highlighted in the Tornado graph.
CR: Cure rate; PPV: Positive predictive value; PR: Progression rate.
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Table 1
Sociodemographic and clinical characteristics for women, stratified by HIV status, attending clinics in I the 








(n = 7238) p-value
‡
Age (years), mean (SD) 33.1 (9.8) 34.2 (8.0) 31.1 (9.5) <0.01
Age (years), median (IQR) 31 (12) 33 (11) 29 (12) <0.01
Education primary school and below, N (%) 10,080 (48%) 3287 (49%) 3010 (42%) <0.01
Income <500,000 Zambian Kwacha per
month (~US$125), N (%)
11,924 (63%) 4108 (68%) 3599 (56%) <0.01
Married, cohabiting husband, N (%) 13,677 (65%) 3514 (53%) 5253 (72%) <0.01
Age at menarche (years), mean (SD) 14.7 (1.8) 14.7 (1.8) 14.7 (1.8) 0.06
Age at first sex (years), mean (SD) 17.8 (2.7) 17.6 (2.6) 18.2 (2.9) <0.01
Time between menarche and age at first sex
(years), mean (SD)
3.2 (2.7) 3.0 (2.5) 3.6 (2.9) <0.01
Time sexually active (years), mean (SD) 15.3 (9.9) 16.6 (8.2) 12.8 (9.5) <0.01
Number of lifetime sexual partners,
median (IQR)
2 (2) 3 (3) 2 (2) <0.01
Number of pregnancies, median (IQR) 3 (3) 3 (3) 3 (3) <0.01
Number of live births, median (IQR) 2 (3) 3 (3) 2 (3) <0.01
Never used a condom with regular partner,
N (%)
12,063 (61%) 2667 (44%) 4289 (63%) <0.01
Ever had a Pap smear, N (%) 571 (3%) 173 (3%) 220 (3%) 0.12
History of bleeding during coitus, N (%) 2043 (10%) 741 (12%) 633 (9%) <0.01
IQR: Interquartile range; SD: Standard deviation.
†
Total n = 21,010 includes 7064 (33.6%) with HIV status unknown.
‡
Statistically significant at a of 0.05 for comparison of covariates between HIV-seropositive versus HIV-seronegative women.
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Table 2
Parameters and ranges used for the estimation of cancers prevented to determine program effectiveness in the 




















VIA positive 0.5 0.25–0.75 0.06 0.056–0.078 Cryotherapy 0.6 0.66–0.85
CIN CIN 1 0.5 0.25–0.75 0.06 0.056–0.078 Local excision 0.6 0.25–0.80
CIN 2/3 0.5 0.25–0.75 0.3 0.2–0.4 Local excision 0.6 0.25–0.80
Early-stage cancer Stage Ia 1 1 1 1 Surgery/XRT 0.9 0.85–1.00
Stage Ib 1 1 1 1 Surgery/XRT 0.7 0.60–0.90
Stage IIa 1 1 1 1 Surgery/XRT 0.7 0.65–0.75
Late-stage cancer Stage 11b 1 1 1 1 XRT 0.6 0.55–0.65
Stage IIIa 1 1 1 1 XRT 0.4 0.35–0.45
Stage IIIb 1 1 1 1 XRT 0.3 0.20–0.40
Stage IVa 1 1 1 1 XRT 0.1 0.00–0.20
Unknown 1 1 1 1 XRT 0.3 0.3




A positive predictive value (PPV) of a screening test reflects the proportion of women who are truly (confirmed by hlstopathology) positive out of 
the total women who are screened positive. Thus, it is the appropriate measure of test performance in settings where screening-negative women 
never get confirmation for true disease (as in this real-world program operation). Note that PPV applies to both VIA and histologic evaluation, such 
that the average estimate of 0.5 reflects that only 50% of VIA-positive women were truly diseased, and 50% of women undergoing histologic 
evaluation had some CIN lesions. The estimate of 1 for early- and late-stage cancers is used since the combination of histological and clinical 
staging procedures plus the low inter/intra-observer variability associated with the histologic diagnosis of invasive cancer assumes some stage of 
cancers is present (hence all women seen for staging have confirmed cancer on histologic evaluation, hence PPV of 1).
§
Adapted from [8,18–22]; ‘Adapted from [22–25].
HIV Ther. Author manuscript; available in PMC 2014 November 19.
